Core Viewpoint - Huaxi Biological Technology Co., Ltd. announced a settlement regarding arbitration with Medytox Inc., leading to the termination of the arbitration process and the planned dissolution of their joint venture, Medybloom Limited, with an expected positive financial impact from asset recovery [1][2][3] Group 1: Arbitration Background and Settlement Progress - The joint venture, Medybloom Limited, was established in May 2015, with both parties holding 50% stakes, focusing on the development and sales of Medytox's medical aesthetic products in mainland China [2] - Due to the inability to achieve the cooperation objectives, Gentix Limited initiated arbitration in January 2023 [2] - The settlement agreement stipulates the termination of arbitration by October 29, 2025, with all related claims withdrawn within ten days of signing [2] Group 2: Joint Venture Dissolution and Financial Impact - Medybloom Limited will be dissolved after the distribution of remaining assets, with Huaxi Biological expecting to recover approximately 9.6 million Hong Kong dollars, positively affecting current profits [3] - The company had previously fully impaired its long-term equity investment in Medybloom by the end of 2023 [3] - The settlement is seen as beneficial for maintaining a cooperative relationship with Medytox, avoiding additional costs associated with arbitration [3]

关于控股子公司与 Medytox 仲裁事项达成和解的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 本次仲裁申请的基本情况 仲裁申请人：钜朗公司 证券代码：688363 证券简称：华熙生物 公告编号：2025-042 华熙生物科技股份有限公司 4、仲裁案件具体情况 公司与 Medytox 在透明质酸原料方面合作多年，为维护双方友好合作关系， 同时为避免因本次仲裁产生的不必要费用支出，经友好协商，钜朗公司与 Medytox 于 2025 年 10 月 29 日签署和解协议，一致同意终止在新加坡国际仲裁 中心进行的仲裁程序，并在和解协议签署日起十天内撤回所有与本次仲裁相关的 诉求。双方还签署了谅解备忘录，旨在探讨在未来进一步扩大彼此合作的方式。 2015 年 5 月 7 日，注册于开曼群岛的原香港交易所上市公司华熙生物科技 有限公司（目前已退市，以下简称"开曼华熙"）与 Medytox 签署合资协议（以 下简称"合资协议"），并根据合资协议的约定于其后在香港注册成立双方各持股 50%的合资公司华熙 ...

Group 1 - The medical beauty sector experienced a decline of 0.14% on October 29, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] - Key stocks in the medical beauty sector showed varied performance, with Jinbo Biological rising by 7.46% and Ai Meike falling by 1.97% [1] Group 2 - The medical beauty sector saw a net outflow of 23.498 million yuan from main funds, while retail investors had a net inflow of 39.3117 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund inflow of 8.119 million yuan, while Ai Meike experienced a significant outflow of 29.5668 million yuan [2] - The overall trend showed that retail investors were more active in the sector, with a net inflow across several stocks despite the main and speculative funds pulling back [2]

Core Viewpoint - Huaxi Bio reported a decline in revenue and net profit for the first three quarters of 2025, but showed signs of recovery in the third quarter with improved profitability and operational efficiency [1] Financial Performance - For the first three quarters of 2025, the company achieved revenue of approximately 3.163 billion yuan, a year-on-year decrease of 18.36% [1] - The net profit attributable to shareholders was about 252 million yuan, down 30.29% year-on-year [1] - Basic earnings per share were 0.52 yuan, reflecting a decrease of 30.67% compared to the previous year [1] Third Quarter Highlights - In the third quarter of 2025, the company reported revenue of 903 million yuan, a year-on-year decline of 15.16% [1] - The net profit attributable to shareholders for the third quarter was 32 million yuan, showing a significant year-on-year increase of 55.63% [1] - The company has maintained a trend of profit recovery for two consecutive quarters, indicating continuous improvement in operational quality and profitability [1] Management and Strategic Adjustments - Since March 2025, the chairman and general manager have led the management team back to the front lines, focusing on systematic adjustments in business philosophy, direction, and talent organization [1] - The company has achieved a significant improvement in operational quality and efficiency through these strategic changes [1] Cost Management - The sales expense ratio in the third quarter decreased to 34.26%, the lowest level in the past five years, attributed to optimized brand communication and channel structure [1] - The net cash flow from operating activities increased by 859% year-on-year, indicating a strong improvement in core operational metrics [1]

MACD金叉信号形成，这些股涨势不错！ 公募基金方面本期较上一季度持股减少的公募基金共计5个，包括华夏上证科创板50成份ETF、华宝中 证医疗ETF、易方达上证科创板50ETF、招商国证生物医药指数A、南方中证500ETF，持股减少占比达 1.32%。本期较上一季度新披露的公募基金共计2个，包括前海联合添瑞一年持有混合A、前海联合添利 债券A。本期较上一季未再披露的公募基金共计160个，主要包括汇添富中证主要消费ETF、科创ETF、 天弘国证生物医药ETF、广发科创50ETF、国泰中证医疗ETF等。 外资态度来看，本期较上一季度持股减少的外资基金共计1个，即香港中央结算有限公司，持股减少占 比达0.65%。本期较上一季未再披露的外资机构即香港中央结算有限公司。 2025年10月29日，华熙生物(688363.SH)发布2025年第三季报。截至2025年10月28日，共有11个机构投 资者披露持有华熙生物A股股份，合计持股量达3.50亿股，占华熙生物总股本的72.61%。其中，前十大 机构投资者包括华熙昕宇投资有限公司、国寿成达(上海)健康产业股权投资中心(有限合伙)、中国工商 银行股份有限公司-易方达上证科创 ...

Core Viewpoint - The company reported a net profit of 32 million yuan for Q3 2025, representing a year-on-year increase of 55.63%, while operating revenue decreased by 15.16% to 903 million yuan, indicating a trend of profit recovery and improved operational quality [5][6][13] Financial Performance - The company achieved a net profit of 0.32 billion yuan in Q3 2025, a 55.63% increase year-on-year [5] - Operating revenue for the same period was 9.03 billion yuan, down 15.16% compared to the previous year [5] - The sales expense ratio decreased to 34.26%, the lowest level in five years, due to optimized brand communication and channel structure [5] - Net cash flow from operating activities increased by 859% year-on-year, indicating significant improvement in core financial metrics [5] Business Strategy - The company is focusing on an integrated business layout from "raw materials to end products," particularly in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [6][7] - The core business, which includes raw materials and medical terminal operations, accounts for approximately 60% of total revenue, showing stable development [6] - The company is enhancing its brand communication and market strategies to align with its research attributes, particularly in the skin science innovation sector [6] Asset Impairment - The company recognized credit impairment losses of 17.54 million yuan due to provisions for bad debts and inventory write-downs in Q3 2025 [11][12] - The total provision for bad debts amounted to 14.08 million yuan, representing 20.38% of the accounts receivable balance [12] - The inventory write-down provision was 5.71 million yuan, accounting for 3.56% of the inventory balance [12][13]

Core Viewpoint - Huaxi Biological reported a decline in revenue and net profit for the first three quarters of 2025, indicating challenges in its core business despite a slight recovery in the third quarter [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 3.163 billion yuan, a year-on-year decrease of 18.36% [1][2]. - The net profit attributable to shareholders was 252.38 million yuan, down 30.29% year-on-year [1][2]. - In Q3 2025, revenue was 903 million yuan, a decline of 15.16% compared to the same period last year, while net profit increased by 55.63% to 31.53 million yuan [2][3]. Cost Management - The increase in Q3 net profit was attributed to a reduction in promotional expenses and an optimized brand communication model, with the sales expense ratio dropping to 34.26%, the lowest in five years [3]. - The company recognized credit impairment losses of 17.54 million yuan and inventory impairment losses of 5.71 million yuan in Q3 2025, impacting total profit by 23.25 million yuan [3][4]. Strategic Investments - Huaxi Biological invested 138 million HKD in Saintno Pharmaceutical, acquiring a 9.44% stake, aiming for business synergy in the innovative drug and medical aesthetics sector [7]. - The investment is expected to leverage Huaxi's expertise in hyaluronic acid to enhance RNAi therapy development, particularly in targeted delivery technologies [7]. Market Position and Challenges - Saintno Pharmaceutical is currently in a "zero revenue, continuous loss" phase, with significant losses reported and no products on the market [8]. - Despite the potential in the weight loss drug market, competition is intense, and the success of integrating innovative drugs with medical aesthetics remains uncertain [7][8].

Core Viewpoint - Huaxi Biological (688363.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - Total operating revenue for the first three quarters reached 3.163 billion yuan, a year-on-year decrease of 18.36% [1] - Net profit attributable to shareholders was 252 million yuan, down 30.29% year-on-year [1] - Basic earnings per share stood at 0.52 yuan [1]

Core Viewpoint - Huaxi Biological announced the provision for asset impairment losses based on the principles of prudence, in accordance with the accounting standards set by the Ministry of Finance [2] Summary by Relevant Categories Financial Performance - For the third quarter of 2025, the company made a provision for bad debts amounting to 18.7159 million yuan for accounts receivable and reversed bad debt provisions of 1.1781 million yuan for other receivables, resulting in a total bad debt provision of 17.5378 million yuan [2]

Core Viewpoint - ECM (Extracellular Matrix) is essential for complex life and civilization, as emphasized by Zhao Yan, Chairman of Huaxi Group and Huaxi Bio [3][4]. Group 1: Strategic Initiatives - Huaxi Bio's core brand, Runbaiyan, has named two venues, "Beijing Wukesong" and "Chongqing Yudong," as "Huaxi Bio·Runbaiyan ECM Center," marking a significant branding milestone [5][8]. - This initiative represents a shift from mere brand exposure to a scientific narrative, integrating ECM into urban settings to reflect the concept of "life converging here, civilization being born" [8][9]. - The ECM strategy is a pioneering move that combines research and practical applications, positioning Huaxi Bio as a leader in the anti-aging sector [8][9]. Group 2: Understanding ECM - ECM is a dynamic network composed of components like hyaluronic acid (HA), collagen, and elastin, playing a crucial role in skin development and regeneration [9][10]. - It serves as a mechanical scaffold for skin cells, facilitating growth and providing essential nutrients and support [10]. - ECM also acts as a signaling hub, regulating cell behavior and maintaining normal bodily functions [10][11]. Group 3: Research and Development - ECM has been recognized as a key factor in aging, with recent studies highlighting its role in cellular communication and regeneration [13][14]. - Huaxi Bio has been at the forefront of ECM research, focusing on the potential of HA in anti-aging applications [20][21]. - The company has developed various molecular weights of HA, establishing a solid foundation for ECM regulation [21][23]. Group 4: Market Positioning - The dual venue naming strategy enhances Huaxi Bio's brand visibility and positions Runbaiyan as a pioneer in the anti-aging market [18][39]. - This approach aligns with the "smiling curve" theory, indicating a transition from technological leadership to brand value enhancement [30][32]. - The initiative aims to educate the market about ECM, improving brand perception and establishing Runbaiyan as a scientific leader in the beauty industry [39][40].